115 related articles for article (PubMed ID: 14985451)
1. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts.
Bani MR; Nicoletti MI; Alkharouf NW; Ghilardi C; Petersen D; Erba E; Sausville EA; Liu ET; Giavazzi R
Mol Cancer Ther; 2004 Feb; 3(2):111-21. PubMed ID: 14985451
[TBL] [Abstract][Full Text] [Related]
2. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
[TBL] [Abstract][Full Text] [Related]
3. Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells.
Appierto V; Villani MG; Cavadini E; Gariboldi M; De Cecco L; Pierotti MA; Lambert JR; Reid J; Tiberio P; Colombo N; Formelli F
Oncogene; 2007 Jun; 26(27):3952-62. PubMed ID: 17213814
[TBL] [Abstract][Full Text] [Related]
4. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.
Chen X; Zhang XY; Shen Y; Fan LL; Ren ML; Wu YP
Oncotarget; 2016 Dec; 7(50):83451-83461. PubMed ID: 27825139
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
[TBL] [Abstract][Full Text] [Related]
6. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
Koussounadis A; Langdon SP; Um I; Kay C; Francis KE; Harrison DJ; Smith VA
BMC Cancer; 2016 Mar; 16():205. PubMed ID: 26964739
[TBL] [Abstract][Full Text] [Related]
7. Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.
Liu D; Hou X; Wu W; Zanfagnin V; Li Y; Correia C; Zhao Z; Zhao C; Liu Z; Zhang T; Fang Z; Wang H; Xu C; Weroha SJ; Kaufmann SH; Dai H
Cell Death Dis; 2021 Aug; 12(8):789. PubMed ID: 34385422
[TBL] [Abstract][Full Text] [Related]
8. [Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].
Konno R
Hum Cell; 2001 Dec; 14(4):261-6. PubMed ID: 11925926
[TBL] [Abstract][Full Text] [Related]
9. Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer.
Liu P; Khurana A; Rattan R; He X; Kalloger S; Dowdy S; Gilks B; Shridhar V
Cancer Res; 2009 Jun; 69(11):4843-50. PubMed ID: 19487294
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
[TBL] [Abstract][Full Text] [Related]
12. Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell.
Xu CZ; Shi RJ; Chen D; Sun YY; Wu QW; Wang T; Wang PH
Int J Clin Exp Pathol; 2013; 6(12):2745-56. PubMed ID: 24294361
[TBL] [Abstract][Full Text] [Related]
13. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
Faratian D; Zweemer AJ; Nagumo Y; Sims AH; Muir M; Dodds M; Mullen P; Um I; Kay C; Hasmann M; Harrison DJ; Langdon SP
Clin Cancer Res; 2011 Jul; 17(13):4451-61. PubMed ID: 21571868
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance.
Fu Y; Hu D; Qiu J; Xie X; Ye F; Lu WG
Int J Gynecol Cancer; 2011 Apr; 21(3):439-44. PubMed ID: 21436692
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors.
Sui M; Chen F; Chen Z; Fan W
Int J Cancer; 2006 Aug; 119(3):712-7. PubMed ID: 16496381
[TBL] [Abstract][Full Text] [Related]
17. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
[TBL] [Abstract][Full Text] [Related]
18. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
19. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
20. Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance.
Zhang J; Zhao J; Zhang W; Liu G; Yin D; Li J; Zhang S; Li H
Int J Gynecol Cancer; 2012 Nov; 22(9):1450-6. PubMed ID: 23051955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
